Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised MOMA Therapeutics on the transaction. MOMA Therapeutics announced it has entered into a collaboration and exclusive license agreement with Bayer to develop...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced a multi-year partnership with NanoVation Therapeutics to develop genetic medicines for rare and cardiometabolic...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised CAMP4 Therapeutics on the transaction. CAMP4 Therapeutics Corporation, a clinical-stage biotechnology company, announced a research collaboration with BioMarin Pharmaceutical aimed at advancing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Vir Biotechnology in the transaction. Vir Biotechnology (Nasdaq: VIR) announced it has entered into an exclusive worldwide license agreement with Sanofi for...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Amylyx Pharmaceuticals in the transaction and Sidley Austin represented Eiger BioPharmaceuticals. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx) announced the acquisition of a...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised FogPharma on the transaction. FogPharma announced a collaboration with ARTBIO Inc. to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Gilgamesh Pharmaceuticals in a transaction. Gilgamesh Pharmaceuticals announced it has entered into a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Novavax Inc. in the transaction. Novavax Inc.(Nasdaq: NVAX) announced it has entered into a co-exclusive licensing agreement with French pharmaceutical company Sanofi...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...
You must be a Standard 1 Year member to access this content.
